[Hiring] Vice President Market Access & Value @Neurogene

Role Description

Neurogene is seeking an accomplished, strategic, and entrepreneurial Vice President of Market Access and Value to lead the development and execution of its U.S. market access strategy as the company advances toward commercialization of innovative gene therapies for patients with rare neurological diseases. Reporting to the Chief Commercial Officer, this executive will play a critical role in preparing Neurogene for the potential launch of NGN-401, an investigational gene therapy for Rett syndrome, while establishing scalable market access capabilities to support the company's broader pipeline.

The Vice President will be responsible for developing comprehensive strategies across:

• Payer engagement
• Reimbursement
• Government programs
• Institutional access
• Contracting
• Value demonstration

A central priority will be addressing the unique economic, operational, and reimbursement complexities associated with high-cost, potentially one-time gene therapies administered at specialized treatment centers.

The ideal candidate brings a successful track record in rare disease commercialization, a sophisticated understanding of the evolving cell and gene therapy reimbursement landscape, and demonstrated ability to translate complex market access challenges into actionable strategies that enable patient access.

This is a unique opportunity to shape the market access foundation of an emerging gene therapy company at a pivotal stage of development.

Accountabilities and Responsibilities

Market Access Strategy & Commercial Leadership

• Develop and execute an integrated U.S. market access strategy supporting the successful commercialization of NGN-401 and future Neurogene therapies.
• Serve as the company's senior market access expert, providing strategic guidance on payer dynamics, reimbursement pathways, access barriers, and emerging healthcare policy developments.
• Translate the unique clinical, economic, and treatment delivery characteristics of gene therapy into differentiated and sustainable access strategies.
• Partner closely with Commercial, Medical Affairs, Finance, Regulatory, Legal, and other functional leaders to ensure market access considerations are integrated into commercialization planning and decision-making.
• Anticipate competitive market dynamics and evolving payer expectations, proactively developing strategies to differentiate Neurogene's access approach.
• Establish clear launch-readiness milestones, performance measures, and risk mitigation strategies to support timely patient access following potential regulatory approval.

Payer Strategy, Medicaid & Government Programs

• Lead the development and execution of comprehensive payer access strategies across commercial insurers, Medicaid, and other relevant government programs.
• Develop a sophisticated understanding of state-specific Medicaid coverage, reimbursement, and payment pathways, particularly as they relate to pediatric rare disease populations and high-cost gene therapies.
• Establish strategic relationships with key payer decision makers, government program stakeholders, and other influential reimbursement organizations.
• Personally lead high-priority payer engagements, complex access discussions, and strategic negotiations as appropriate.
• Evaluate and develop innovative contracting and reimbursement approaches, including outcomes-based agreements and alternative payment models where appropriate.
• Monitor emerging federal and state policy developments, including CMS initiatives related to cell and gene therapy access, and assess their potential implications for Neurogene.
• Partner with Legal, external policy experts, and executive leadership to inform government policy engagement and reimbursement advocacy.

Institutional Reimbursement & Treatment Center Access

• Lead the development and execution of institutional reimbursement strategies designed to support the financial readiness of specialized treatment centers administering Neurogene therapies.
• Develop expertise-driven solutions addressing hospital reimbursement, coding, coverage, payment pathways, and site-of-care economics.
• Evaluate inpatient and outpatient reimbursement dynamics, hospital acquisition and administration costs, financial exposure, and other institutional barriers associated with gene therapy delivery.
• Develop strategies to address reimbursement variability across commercial and government payers, including institution-specific payment challenges and alternative reimbursement arrangements.
• Partner with Customer Engagement, Patient Services, Commercial Supply Chain, and other stakeholders to integrate institutional financial readiness into broader treatment-center launch planning.
• Identify and mitigate financial barriers that could prevent clinically qualified treatment centers from offering therapy to eligible patients.
• Establish measurable institutional access-readiness criteria and processes for identifying and resolving reimbursement challenges before and after launch.

Pricing, Contracting & Financial Strategy

• Partner with Commercial leadership and Finance to inform product pricing strategy, incorporating payer insights, competitive dynamics, access implications, and long-term financial sustainability.
• Lead the development of payer contracting strategies, reimbursement assumptions, and innovative access arrangements appropriate for rare disease gene therapies.
• Collaborate with Finance and Commercial Analytics to inform gross-to-net assumptions, financial forecasts, and scenario planning.
• Assess the implications of pricing and contracting decisions across Medicaid, commercial payers, and institutional treatment settings.
• Provide strategic recommendations to executive leadership regarding access-related financial risks, opportunities, and trade-offs.

Health Economics, Outcomes Research & Value Demonstration

• Partner with Medical Affairs to develop an integrated value evidence strategy that supports payer decision-making and demonstrates the clinical and economic value of Neurogene therapies.
• Lead the identification of payer evidence requirements and access-related evidence gaps, informing HEOR priorities and economic modeling.
• Guide the development of payer value propositions, budget impact analyses, economic models, and other evidence-based access tools.
• Ensure that relevant patient, caregiver, healthcare utilization, and long-term outcomes considerations are appropriately incorporated into value demonstration strategies.
• Collaborate with Medical Affairs on real-world evidence priorities and long-term evidence-generation approaches that support reimbursement and access objectives.
• Translate complex clinical and economic evidence into compelling, scientifically accurate, and compliant value communications for appropriate external stakeholders.

Organizational Development & Cross-Functional Integration

• Build and lead a high-performing, scalable Market Access organization capable of supporting Neurogene's transition from clinical development to commercial operations.
• Develop the organizational design, talent acquisition roadmap, operating model, and resource strategy required to establish critical market access capabilities.
• Determine the optimal balance of internal talent, external partners, consultants, and field-based resources to support launch readiness and ongoing commercialization.
• Establish clear functional accountabilities, performance expectations, and cross-functional operating processes.
• Partner closely with Patient Services and Commercial Supply Chain to ensure integrated planning across reimbursement support, patient access, distribution, and treatment-center needs.
• Depending on organizational needs and the experience of the selected candidate, responsibilities may expand to include leadership of Patient Services and/or Trade and Channel functions.
• Foster a collaborative, accountable, and patient-centered culture that values strategic thinking, operational excellence, and agile execution.

International Market Access Collaboration

• Provide strategic input into future international pricing, reimbursement, and market access planning as Neurogene evaluates opportunities beyond the United States.
• Partner with internal and external stakeholders to identify global evidence requirements, access considerations, and potential implications of U.S. pricing and reimbursement decisions.
• Support the development of scalable market access approaches that may inform future geographic expansion.

Qualifications

• Bachelor's degree in business, life sciences, healthcare, economics, or a related field.
• Advanced degree in business, healthcare, public health, economics, or a related discipline, is a plus.

Requirements

• 15+ years preferred - progressive leadership experience in pharmaceutical or biotechnology market access, including demonstrated responsibility for developing and executing U.S. access strategies.
• Proven success supporting the launch and commercialization of rare disease, orphan, or highly specialized therapies.
• Deep understanding of the U.S. healthcare reimbursement environment, including commercial payers, Medicaid, managed care, and government reimbursement programs.
• Demonstrated expertise in institutional reimbursement, hospital economics, coding and payment pathways, and access considerations for complex, high-cost therapies.
• Experience developing payer value propositions and collaborating on HEOR and evidence-generation strategies.
• Demonstrated ability to build, lead, and develop high-performing teams and scalable organizational capabilities.
• Established ability to engage credibly with senior payer stakeholders, institutional decision-makers, and executive leadership.
• Strong strategic, analytical, financial, and communication skills, with demonstrated ability to translate complex challenges into actionable business solutions.
• Proven success operating cross-functionally in dynamic, evolving organizations.

Company Description

Neurogene is dedicated to treating devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. The company is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.